Annuncio • May 06
Twist Bioscience Corporation Expands Clonal Genes Offering to Include Long and Complex Sequences Twist Bioscience Corporation had expanded its clonal genes portfolio with the early access launch of Complex Genes. Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products. Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics. Sequences with complex elements have historically been difficult to produce at commercial scale. Leveraging its proprietary silicon-based DNA synthesis platform and improved downstream processes in manufacturing, automation, and sequencing, Twist can now reliably synthesize and deliver these previously out-of-reach complex sequences at scale. Complex sequence elements such as short tandem, inverted and long repeats, as well as high or low GC content and more, can be essential components of customers’ sequences in the development of nucleic acid therapeutics such as cell and gene therapies, mRNA therapies and more. The ability to synthesize complex sequences is also essential for AI-enabled drug discovery where researchers need their AI-generated sequences manufactured exactly, without adding a step to alter the sequences for manufacturability. By delivering genes with novel and complex structures combined with a transparent online ordering and tracking process, Twist enables customers to advance cutting edge research, empowering the development of new and next-generation therapeutics. Twist can synthesize and deliver complex sequences including short tandem repeats, inverted repeats, long repeats, homopolymers up to 30 base pairs and localized regions of high or low GC content. These are features commonly found in sequence elements such as advanced promoters, UTRs, ITRs, secondary structures and GS linkers. When customers submit sequences, they will receive a complexity score and a manufacturability score, for full transparency during the ordering process. Twist reliably delivers constructs ranging from 300 to 7,000 base pairs within 15 business days standard turnaround time, regardless of order scale or complexity. All Twist Clonal Genes can be cloned into a Twist catalog vector, or an onboarded vector of the customer’s choice. Reported Earnings • May 05
Second quarter 2026 earnings released: US$0.71 loss per share (vs US$0.66 loss in 2Q 2025) Second quarter 2026 results: US$0.71 loss per share (further deteriorated from US$0.66 loss in 2Q 2025). Revenue: US$110.7m (up 19% from 2Q 2025). Net loss: US$44.0m (loss widened 12% from 2Q 2025). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Annuncio • Apr 21
Twist Bioscience Corporation to Report Q2, 2026 Results on May 04, 2026 Twist Bioscience Corporation announced that they will report Q2, 2026 results Pre-Market on May 04, 2026 Recent Insider Transactions • Feb 24
Insider recently sold €1.7m worth of stock On the 17th of February, Paula Green sold around 39k shares on-market at roughly €44.30 per share. This transaction amounted to 55% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €10m more than they bought in the last 12 months. Annuncio • Feb 10
Twist Bioscience Corporation Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes Twist Bioscience Corporation launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist's library preparation portfolio, with advantages enabled by Twist in-house developed enzymes, including a previously developed ligase as well as a newly developed polymerase. Engineered for next generation sequencing applications, the specialized TrueAmp polymerase maximizes coverage across typically hard-to- sequence regions of the genome, while maintaining high accuracy during DNA copying. The kit ensures high yields even from low- input or degraded starting samples, which minimizes amplification-introduced errors and results in more usable high-quality data. To streamline large-scale workflows, the Twist TrueAmp Library Prep kit has been validated with the Twist HT-UDI adapters system, allowing for up to 3,072 unique indexes as well as Twist UMI adapters, ensuring precise strand identification and efficient multiplexing. To serve customers across sequencing applications, Twist developed a complementary PCR-free version of the kit for researchers conducting whole genome sequencing (WGS). Leveraging Twist's engineered ligase, the Twist PCR-Free WGS library Preparation Kit efficiently converts starting DNA without bias commonly seen in whole genome sequencing. Precly optimized enzymatic fragmentation conditions deliver consistent outputs that maximize sequencing efficiency and improve data quality. The PCR-Free WGS Kit allows Twist to further serve customers using whole genome sequencing for approaches where low pass sequencing is sufficient, such as rare disease, while in parallel providing researchers working in areas that require deep sequencing, such as cancer, with panels and other tools to support their research. Recent Insider Transactions • Feb 08
VP & Chief Accounting Officer recently sold €278k worth of stock On the 4th of February, Robert Werner sold around 7k shares on-market at roughly €38.72 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €8.7m more than they bought in the last 12 months. Reported Earnings • Feb 03
First quarter 2026 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2025) First quarter 2026 results: US$0.50 loss per share (improved from US$0.53 loss in 1Q 2025). Revenue: US$103.7m (up 17% from 1Q 2025). Net loss: US$30.5m (loss narrowed 3.4% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. New Risk • Feb 02
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 5.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings are forecast to decline by an average of 5.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$98m net loss in 3 years). Significant insider selling over the past 3 months (€951k sold). Annuncio • Jan 12
Twist Bioscience Corporation to Report Q1, 2026 Results on Feb 02, 2026 Twist Bioscience Corporation announced that they will report Q1, 2026 results Pre-Market on Feb 02, 2026 Annuncio • Jan 09
Twist Bioscience Corporation, Annual General Meeting, Feb 05, 2026 Twist Bioscience Corporation, Annual General Meeting, Feb 05, 2026. Annuncio • Dec 04
Twist Bioscience Corporation Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research Twist Bioscience Corporation launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers' pre-clinical studies. With animal origin-free (AOF) and transfection-grade preps and target yield options, Twist can support the nucleic acid therapeutics discovery and development process by ensuring consistently manufactured DNA, aligning with customer specifications and reducing variability and risk in their discovery programs. Customers entering the preclinical phase often have specific quality requirements, such as animal origin-free, and low, or endotoxin-free, for DNA that will be transferred into delicate cells. To meet these standards, Twist offers low and endotoxin-free transfection grade preps, as well as AOF preps available with TSE and BSE certificates for verification of quality standards. In addition, customers can receive target yields for prep sizes 4ug to 10ug to ensure consistent and precise mass in every prep. The platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. Reported Earnings • Nov 15
Full year 2025 earnings released: US$1.30 loss per share (vs US$3.60 loss in FY 2024) Full year 2025 results: US$1.30 loss per share (improved from US$3.60 loss in FY 2024). Revenue: US$376.6m (up 20% from FY 2024). Net loss: US$77.7m (loss narrowed 63% from FY 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe. Recent Insider Transactions • Nov 05
Co-Founder recently sold €853k worth of stock On the 30th of October, Emily Leproust sold around 31k shares on-market at roughly €27.19 per share. This transaction amounted to 7.2% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €862k. Emily has been a net seller over the last 12 months, reducing personal holdings by €4.1m. Annuncio • Oct 23
Twist Bioscience Corporation to Report Q4, 2025 Results on Nov 14, 2025 Twist Bioscience Corporation announced that they will report Q4, 2025 results Pre-Market on Nov 14, 2025 Recent Insider Transactions • Oct 10
Co-Founder recently sold €862k worth of stock On the 6th of October, Emily Leproust sold around 31k shares on-market at roughly €27.48 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Emily has been a net seller over the last 12 months, reducing personal holdings by €3.4m. Breakeven Date Change • Oct 02
Forecast to breakeven in 2028 The 6 analysts covering Twist Bioscience expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$750.0k in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule. Board Change • Sep 15
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Director Trynka Blake was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Aug 20
Twist Bioscience Corporation Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution Twist Bioscience Corporation launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. The Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel's coverage spans genomic alterations and genomic signatures and can detect base institutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis. Reported Earnings • Aug 07
Third quarter 2025 earnings released: EPS: US$0.34 (vs US$1.47 loss in 3Q 2024) Third quarter 2025 results: EPS: US$0.34 (up from US$1.47 loss in 3Q 2024). Revenue: US$96.1m (up 18% from 3Q 2024). Net income: US$20.4m (up US$106.0m from 3Q 2024). Profit margin: 21% (up from net loss in 3Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Annuncio • Aug 07
Twist Bioscience Corporation Appoints Trynka Shineman Blake to Its Board of Directors and Audit Committee Twist Bioscience Corporation announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. Ms. Shineman Blake previously served as CEO of Vistaprint (a division of Cimpress) focused on building a better way for microbusinesses to promote themselves. Prior to her tenure as CEO of Vistaprint, she held various positions of increasing responsibility at Vistaprint, including president of North America, executive vice president of global marketing and chief customer officer. During her tenure at Vistaprint, Ms. Shineman Blake played a pivotal role in scaling the business from under $100 million to more than $1 billion in revenue. She aligned the organization under a customer-centric culture, led a comprehensive re-architecture of the company’s technology platform to accelerate the pace of product launches and nurtured an innovation portfolio that expanded Vistaprint’s offerings into new markets and services. Before Vistaprint, she held senior positions at PreVision Marketing, a boutique analytic and marketing agency (acquired by Valassis). Ms. Shineman Blake serves on the boards of several public and private companies, including Tripadvisor, Semrush, Captura, a Charlesbank company, and Steer. She previously served on the boards of Ally Financial Inc. and UBM, PLC; the Management Board of Vistaprint (Cimpress) and the Board of Trustees for the Mass Technology Leadership Council. Ms. Shineman Blake holds a B.A. in psychology from Cornell University and an M.B.A. from Columbia Business School. Annuncio • Aug 01
Twist Bioscience Corporation Expands in Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model Twist Bioscience Corporation announced the launch of a humanized transgenic (HuTg) mouse model to expand and complement its offering of antibody discovery services and further streamline monoclonal antibody discovery. The HuTg mouse model generates robust immune responses and human antibody repertoires to accelerate lead discovery and optimization. By using this platform, the company enable Twist customers to identify fully human hits in weeks instead of months and streamlines translation into the clinic. This new offering expands and complements Twist's in vivo antibody discovery capabilities as it can be paired with Twist's DiversimAb mouse model to maximize epitope coverage and also paired with B cell screening platforms. Annuncio • Jul 14
Twist Bioscience Corporation to Report Q3, 2025 Results on Aug 04, 2025 Twist Bioscience Corporation announced that they will report Q3, 2025 results Pre-Market on Aug 04, 2025 Annuncio • Jul 07
Twist Bioscience Corporation Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of Format Twist Bioscience Corporation accelerated its Express turnaround time for all Twist Gene Fragments with a turnaround time starting at two business days for both adapters off and adaptors on configurations. Twist Gene Fragments are designed to simplify the process of ordering synthetic DNA by offering a reliable and cost-effective solution for researchers. Fragments ship within two to four business days, for one or tens of thousands of Gene Fragments. Twist provides flexible delivery formats including tubes, plates, normalization and resuspension, as well as adapter addition, without impact to turnaround time or cost. Twist will offer gene Fragments without adaptors as a standard offering, eliminating the fee previously charged for removing adaptors. At Twist, company deliver Gene Fragments quickly, with a typical processing time of just 2-4 business days before turning product over to the shipping carrier. This rapid turnaround time reflects the efficiency of facilities, ensuring orders are manufactured quickly and reliably. company platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead.